4.8 Article

Screening of DUB activity and specificity by MALDI-TOF mass spectrometry

期刊

NATURE COMMUNICATIONS
卷 5, 期 -, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms5763

关键词

-

资金

  1. Medical Research Council UK
  2. Division of Signal Transduction Therapy (DSTT) (AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Janssen Pharmaceutica, Merck KGaA and Pfizer)
  3. MRC Protein Phosphorylation and Ubiquitylation Unit
  4. MRC [MC_UU_12016/8, MC_G1000735, MC_UP_A500_1020, MC_UU_12016/2, G1100713, MC_UU_12016/5] Funding Source: UKRI
  5. Medical Research Council [MC_UU_12016/8, MC_G1000735, G1100713, MC_UP_A500_1020, MC_UU_12016/2, MC_UU_12016/5] Funding Source: researchfish

向作者/读者索取更多资源

Deubiquitylases (DUBs) are key regulators of the ubiquitin system which cleave ubiquitin moieties from proteins and polyubiquitin chains. Several DUBs have been implicated in various diseases and are attractive drug targets. We have developed a sensitive and fast assay to quantify in vitro DUB enzyme activity using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry. Unlike other current assays, this method uses unmodified substrates, such as diubiquitin topoisomers. By analysing 42 human DUBs against all diubiquitin topoisomers we provide an extensive characterization of DUB activity and specificity. Our results confirm the high specificity of many members of the OTU and JAB/MPN/Mov34 metalloenzyme DUB families and highlight that all USPs tested display low linkage selectivity. We also demonstrate that this assay can be deployed to assess the potency and specificity of DUB inhibitors by profiling 11 compounds against a panel of 32 DUBs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据